bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib
Phase 2/3UNKNOWN 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oesophagogastric Cancer
Conditions
Oesophagogastric Cancer
Trial Timeline
Oct 1, 2007 → Dec 1, 2017
NCT ID
NCT00450203About bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib
bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib is a phase 2/3 stage product being developed by Roche for Oesophagogastric Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT00450203. Target conditions include Oesophagogastric Cancer.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00450203 | Phase 2/3 | UNKNOWN |